Current strategies for targeting MSCs are still focused on targeting tumor growth-promoting and immune-suppressing factors released by MSCs and on inhibiting the recruitment of MSCs by tumor cells, for example, targeting MSCs to produce the C-X-C motif chemokine ligand 12 (CXCL12), inhibiting metastasis of tumor cells, and enhancing the efficacy of ICI therapy [81, 82]. This evidence concerns the gene CXCL12 and neoplasm.